Sign in
TerminatedPhase 1

A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia

Key facts

Who runs it
Eli Lilly and Company
Where
Singapore1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
41 people enrolled
Started
14 Nov 2022
Ended
10 Jan 2024
Type of study
Interventional, 8 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • LY3875383
  • Placebo
Record updated
4 June 2025
Why it stopped
The study was terminated due to a change in risk/benefit ratio, which no longer favoured continued development.

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • All participants:
  • Have a body mass index (BMI) between 18.5 and 40 kilograms per square meter (kg/m²), inclusive
  • Males who agree to follow contraceptive requirements, or women not of childbearing potential (WNOCBP); Healthy participants (Part A):
  • Participants must be overtly healthy, as determined by medical evaluation; For Part B:
  • Participants must be first-generation Japanese, defined as the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan; Hypertriglyceridemia participants (Parts C and D):; For Part C:
  • Have history of very high triglyceride (lipid) level 500 mg/dL ≤ TG <2000 mg/dL, which needs to be further confirmed at screening
  • Participants must be on a lipid-modifying diet and can be on stable lipid-lowering drugs (LLDs) for at least 8 weeks before screening and plan to continue the same throughout the study duration; For Part D:
  • Have history of high triglyceride (lipid) level between 150 mg/dL and 500 mg/dL inclusive at pre-screening or based on medical history and confirmed at screening and Low-density lipoprotein cholesterol (LDL-C) level of ≥40 mg/dL
  • Participants must be on a stable moderate or high-intensity dose of a statin for at least 8 weeks before screening and plan to continue the same medication and dose throughout the study duration

Who cannot take part

  • Have donated blood of more than 500 mL within the previous 3 months
  • Have one of the following viral infections: hepatitis B virus, hepatitis C virus or human immunodeficiency virus (HIV)
  • All participants:
  • Participants must not be currently participating in or completed a clinical trial within the last 30 days
  • Participants must not be heavy alcohol drinkers or cigarette smokers; For Part C: Have active pancreatitis within the last 6 months

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main purpose of this study is to determine the tolerability and side effects related to LY3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (TG) levels.The study will also assess how fast LY3875383 gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either LY3875383 or placebo.The study will be conducted in four parts (A, B, C and D) and may last up to approximately 28 to 56 weeks including screening.

The 8 groups in the trial

  • LY3875383 (Part A)Treatment being tested

    Single-ascending doses of LY3875383 administered subcutaneously (SC).

    Treatment: LY3875383

  • LY3875383 (Part B)Treatment being tested

    Single doses of LY3875383 administered SC.

    Treatment: LY3875383

  • LY3875383 (Part C)Treatment being tested

    Single doses of LY3875383 administered SC.

    Treatment: LY3875383

  • LY3875383 (Part D)Treatment being tested

    Single doses of LY3875383 administered SC.

    Treatment: LY3875383

  • Placebo (Part A)Placebo, for comparison

    Placebo administered SC.

    Treatment: Placebo

  • Placebo (Part B)Placebo, for comparison

    Placebo administered SC.

    Treatment: Placebo

  • Placebo (Part C)Placebo, for comparison

    Placebo administered SC.

    Treatment: Placebo

  • Placebo (Part D)Placebo, for comparison

    Placebo administered SC.

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia
Record updated
4 June 2025